MedTrace Logo

African American Study of Kidney Disease and Hypertension

NCT04364139 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1094

Last updated 2020-04-27

No results posted yet for this study

Summary

The AASK is a multicenter, randomized, controlled clinical trial using a 2 × 3 factorial design to evaluate the effects of level of blood pressure control and type of anti-hypertensive medication on progression of chronic renal disease among African American men and women with chronic renal insufficiency caused by hypertension (hypertensive nephrosclerosis).

Conditions

  • Hypertensive Nephrosclerosis
  • Chronic Renal Insufficiency

Interventions

OTHER

MAP goal less than or equal to 92 mm Hg

Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg

OTHER

MAP goal 102-107 mm Hg

Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg

DRUG

Ramipril

An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d

DRUG

Amlodipine

A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d

DRUG

Metoprolol

A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • JENNIFER GASSMAN · CLEVELAND CLINIC LERNER COM-CWRU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-02-01
Primary Completion
2001-09-30
Completion
2007-06-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04364139 on ClinicalTrials.gov